GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...

Len Friedland, MD, Vice President of Scientific Affairs and Public Health, GSK, said: “We are excited to share data ... Risk Factors for Herpes Zoster Infection: A Meta-Analysis. Open Forum Infect Dis ...

Data science is one of the most current career choices today, especially in a data-driven world. Today, more businesses rely on data for making strategic decisi ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a ...

Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer.

You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis. So, if you’re still on the fence about whether GSK plc (ADR) is a buy, ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Kacholia turned heads when he exited these stocks between December 2023 and June 2024. Was it a mistake or will his decision ...

GSK plc (ADR)’s stock is NA in 2024, NA in the previous five trading days ... unbiased research and actionable analysis. A+ Investor adds to our qualitative teaching with a powerful data suite to help ...